The Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to Covid-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children age 12 to 15 and 94% effectiveness for those age 16 to 18.
The study included 464 patients – 179 hospitalized with Covid-19 and 285 hospitalized for other reasons – across 19 pediatric hospitals in 16 states between June and September 2021, a time period when the Delta variant was dominant. The majority of patients had at least one underlying condition (72%) and attended in-person school (68%), and most patients were from southern states, as Covid-19 transmission was high in that region during this timeframe.
Patients were considered fully vaccinated against Covid-19 if they had received their second dose of the Pfizer/BioNTech vaccine at least 14 days before illness onset. Those partially vaccinated – with only one dose or with less than 14 days since the second dose – were excluded from the analysis.
Among the 179 patients hospitalized with Covid-19 in the study, 97% were unvaccinated. All of the critically ill patients were unvaccinated, including about 43% (77 patients) were admitted to an intensive care unit, 29 received life support during hospitalization and two died.
Since August 2020, more than 65,000 children have been hospitalized with Covid-19 and nearly 700 have died, according to CDC data.
Clinical trial data from Pfizer/BioNTech found the vaccine to be 100% effective against hospitalization among children age 12 to 15, and this real-world analysis also found vaccination to be highly effective in reducing the risk of hospitalization among those age 12 to 18.
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.
Currently, 46% of children age 12 to 15 and 54% of those age 16 to 17 are fully vaccinated, according to CDC data, a smaller share than any adult age group.
“(These) findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19,” according to the study authors. “These data suggest that increasing vaccination coverage among this group could reduce the incidence of severe COVID-19 in the United States. Further, as in-person school attendance increases, multicomponent preventive measures to reduce the incidence of severe COVID-19 among adolescents, including vaccination, are imperative.”
